Grains of Truth: New EAT-GlobeScan Global Consumer Research on Healthy and Sustainable Food Systems
Affordability and Availability are the Biggest Challenges to Healthy and Sustainable Diets OSLO, Norway, Sept. 23, 2021 /PRNewswire/ -- Just half of people worldwide (53%) find buying healthy and sustainable food easy according to a new global consumer research survey conducted by GlobeScan, an insights and strategy consultancy, and EAT, the science-based non-profit for global food system transformation. However,...
The First US World-Class Bioscience Design Corporation Officially Launched
TAIPEI, Sept. 23, 2021 /PRNewswire/ -- TCI Co., Ltd. set up a subsidiary in the United States for the first time in 2019 to expand its business footprint and bring its successful experience in Asia to the United States. After two years of continuous effort, it has accumulated a series of extensive milestones. In August 2021, TCI acquired NewAge...
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Therapy for Esophageal Squamous Cell Carcinoma (ESCC)
SAN FRANCISCO and SUZHOU, China, Sept. 23, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for...
MedAlliance announces completion of enrollment in Japanese SELUTION SLR™ Study
GENEVA, Sept. 23, 2021 /PRNewswire/ -- MedAlliance, with its Japanese partner MDK Medical, has completed enrollment in the clinical study of its novel Sirolimus Drug Eluting Balloon (DEB), SELUTION SLR™, for the treatment of peripheral arterial disease (PAD). This follows the acceptance of a Clinical Trial Notification (CTN) by Japan's Pharmaceutical and Medical Device...
Ascentage Pharma’s MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melanoma
SUZHOU, China, and ROCKVILLE, MD, Sept 23, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its novel MDM2-p53 inhibitor alrizomadlin (APG-115) has been granted a Fast Track Designation (FTD) by the US Food and...
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
VANCOUVER, British Columbia and SHANGHAI, Sept. 23, 2021 /PRNewswire/ -- AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, "Everest") announced today that they have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by Everest. The partnership will help to expand Everest's portfolio of novel medicines across multiple indications,...
United Imaging Announces FDA Clearance for its Versatile Ultra-Premium Scanner, the uCT® ATLAS
HOUSTON, Sept. 22, 2021 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced FDA clearance for the uCT ATLAS, the latest in the company's Computed Tomography (CT) portfolio of scanners and the 25th FDA clearance for the company overall. "I am incredibly excited to bring this equipment to market in the U.S.," said David...
INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico
News follows recent regulatory authorizations to proceed with the trial in Brazil and the Philippines INOVIO and partner Advaccine are collaborating on the global Phase 3 trial in regions underserved by COVID-19 vaccines; to focus on Latin America, Asia, and Africa PLYMOUTH MEETING, Pa., Sept. 22, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to...
Clover’s COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
Trial enrolled over 30,000 adult & elderly participants across 4 continents; 100% of SARS-CoV-2 strains observed in efficacy analysis were variants (Delta was predominant strain) Primary and secondary efficacy endpoints were successfully met 100% efficacy against severe COVID-19 & hospitalization and 84% efficacy against moderate-to-severe COVID-19 caused by any...
pHOXBIO Announces Breakthrough Clinical Trial Results Concluding Prophylactic Nasal Spray Prevents Infection from SARS-CoV-2
- pHOXWELL significantly reduced SARS-CoV-2 infection by 63% with tolerability comparable to placebo in high-risk population of healthcare workers - Novel self-administered nasal spray designed to augment existing preventive measures for SARS-CoV-2, including PPE and vaccines - Regulatory filing initiated in India for SARS-CoV-2 prevention claim - Company exploring strategic alternatives to...
